ARTICLE IN PRESSGOOO SCIENCEANNALSOFETTER MEDICINEONCOLOGYhuuo noaon i oncoloSPECAL ARTICLEOncogene-addicted metastatic non-small-cell lung cancer:ESMO ClinicalPractice Guideline for diagnosis,treatment and follow-upL E.Hendriks,K.M.Kerr J.Menis3,T.S.Mok,U.Nestle5,6,A.Passaro,S.Peters,D.Planchard,E.F.Smit0,11B.J.Solomon12,G.Veronesi13,14&M.Reck'5,on behalf of the ESMO Guidelines Committee"Department of Pulmonology,GROW School for Oncology and Reproduction,Maastricht University Medical Center,Maastricht,The Netherlands;Aberdeen RoyalInfirmary,Aberdeen University Medical School,Aberdeen,UK;3Medical Oncology Department,University and Hospital Trust of Verona,Verona,Italy;+Department ofCinical Oncology,The Chinese University of Hong Kong,Prince of Wales Hospital,Hong Kong,China;SDepartment of Radiation Oncology,University Hospital Freiburg,Freiburg;Department of Radiation Oncology,Kliniken Maria Hilf,Moenchengladbach,Germany;'Division of Thoracic Oncology,European Institute of Oncology IRCCS,Milan,Italy;Department of Oncology,Centre Hospitalier Universitaire Vaudois,Lausanne University,Lausanne,Switzerland;epartment of Medical Oncology,Thoracic Group,Gustave-Roussy,Villejuif,France;Thoracic Oncology Service,Netherlands Cancer Institute,Amsterdam;Department of Pulmonary Diseases,LeidenUniversity Medical Center,Leiden,The Netherlands;Department of Medical Oncology,Peter MacCallum Cancer Centre,Melbourne,Australia;3Faculty of Medicineand Surgery-Vita-Salute San Raffaele University,Milan;Division of Thoracic Surgery,IRCCS San Raffaele Scientific Institute,Milan,Italy;5Department of ThoracicOncology,Airway Research Center North,German Center for Lung Research,Lung Clinic,Grosshansdorf,GermanyAvailable online XXXKey words:ESCAT,ESMO Clinical Practice Guideline(CPG),ESMO-MCBS,oncogene-addicted metastatic non-small-celllung cancer(mNSCLC),treatment,targeted therapyINCIDENCE AND EPIDEMIOLOGYtherapy.The frequency of oncogenic drivers in NSCLC as wellDetails on incidence and epidemiology are covered in theas general discussion of testing strategy and methodology,Supplementary Material Section 1,available at https://doi.including the use of liquid biopsies,can be found in theorg/10.1016/j.annonc.2022.12.009.Supplementary Material Section 3,available at https://doi.org/10.1016/j.annonc.2022.12.009.Many parameters might determine which tests areDIAGNOSIS,PATHOLOGY AND MOLECULAR BIOLOGYrequired;pre-eminent amongst them is access to appro-Diagnostic procedurespriate drugs.Testing is mandatory for oncogenic drivers forDetails on diagnostic procedures are covered in thewhich drugs are approved for routine usage.Broader testingSupplementary Material Section 2,available at https://doi.org/may be used to support early drug access or clinical trials.2310.1016/j.annonc.2022.12.009.See Supplementary Figure S1,For personalised therapy approaches,European Society foravailable at https://doi.org/10.1016/j.annonc.2022.12.009 forMedical Oncology (ESMO)Scale for Clinical Actionab
